Bioenergetics - PowerPoint PPT Presentation

1 / 28
About This Presentation
Title:

Bioenergetics

Description:

Do accelerate rate of reaction (kinetics) Highly specific for substrate/reactant ... No relationship between G and rate of a reaction (kinetics) ... – PowerPoint PPT presentation

Number of Views:41
Avg rating:3.0/5.0
Slides: 29
Provided by: CalSt6
Category:

less

Transcript and Presenter's Notes

Title: Bioenergetics


1
Bioenergetics
  • Study of energy transformations in living
    organisms
  • Thermodynamics
  • 1st Law Conservation of E
  • Neither created nor destroyed
  • 2nd Law Events proceed from higher to lower E
    states
  • Entropy always increases
  • Universe system surroundings

2
Bioenergetics
  • (E content of system) ?H (useful free E) ?G
    (E lost to disorder) T?S
  • Gibbs Free Energy ?G ?H - T?S
  • If ?G negative, then rxn is exergonic,
    spontaneous
  • If ?G positive, then rxn is endergonic, not
    spontaneous
  • Standard conditions (?G) 25oC, 1M each
    component, pH 7, H2O at 55.6M

3
Bioenergetics
  • A B lt--gt C D
  • Rate of reaction is directly proportional to
    concentration of reactants
  • At equilibrium, forward reaction backward
    reaction
  • k1AB k2CD
  • Rearrange
  • k1/k2 (CD)/(AB) Keq
  • Relationship between ?G and Keq is
  • ?G -2.303 R T log Keq
  • If Keq gt1, ?G is negative, rxn will go forward
  • If Keq lt1, ?G is positive, rxn will go backward

4
(No Transcript)
5
  • ?G is a fixed value at standard conditions
  • ?G under actual cellular conditions can be
    different
  • e.g., for ATP hydrolysis inside a cell, can
    approach ?G -12 kcal/mol
  • We will work with ?G values

6
Coupling endergonic and exergonic rxns
Glutamic acid (Glu) NH3 --gt Glutamine
(Gln) ?G3.4 kcal/mol
ATP --gt ADP Pi ?G-7.3
kcal/mol -----------------------------------------
-----------------------------------------------
Glu ATP NH3 --gt Gln ADP
Pi ?G-3.9 kcal/mol Glutamyl phosphate is the
common intermediate
7
ATP --gt ADP Pi ?G -7.3 kcal/mol ADP Pi
--gt ATP ?G 7.3 kcal/mol C(diamond) O2
--gt CO2 ?G -94.8 kcal/mol PEP --gt pyruvate
Pi ?G -14.8 kcal/mol C(graphite) O2 --gt
CO2 ?G -94.1 kcal/mol P-creatine --gt
creatine Pi ?G -11.0 kcal/mol G6-P --gt
glucose Pi ?G -3.0 kcal/mol 1,3-BPG --gt
3PG Pi ?G -12.5 kcal/mol ------------------
--------------------------------------------------
-------------------- What is ?G of PEP ADP
--gt pyruvate ATP ------------------------------
--------------------------------------------------
-------- What is ?G of G6-P ADP --gt glucose
ATP What is ?G of P-creatine ADP --gt
creatine ATP What is ?G of C(s, diamond) --gt
C(s, graphite)
8
Equilibrium vs steady state
  • Cells are open systems, not closed systems
  • O2 enters, CO2 leaves
  • Allows maintenance of reactions at conditions far
    from equilibrium

O2
9
  • Reqd in small amounts
  • Not altered/consumed in rxn
  • No effect on thermodynamics of rxn
  • Do not supply E
  • Do not determine product/reactant ratio (Keq)
  • Do accelerate rate of reaction (kinetics)
  • Highly specific for substrate/reactant
  • Very few side reactions (i.e. very clean)
  • Subject to regulation
  • No relationship between ?G and rate of a reaction
    (kinetics)
  • Why might a favorable rxn not occur rapidly?

Biological Catalysts
10
(No Transcript)
11
Overcoming the activation energy barrier (EA)
  • Bunsen burner CH4 2O2 --gt CO2 2H2O
  • The spark adds enough E to exceed EA (not a
    catalyst)
  • Metabolism burning glucose
  • Enzyme lowers EA so that ambient fluctuations in
    E are sufficient

12
Overcoming the activation energy barrier (EA)
  • Bunsen burner CH4 2O2 --gt CO2 2H2O
  • The spark adds enough E to exceed EA
  • Metabolism burning glucose
  • Enzyme lowers EA so that ambient fluctuations in
    E are sufficient

Catalyst shifts EA line to left lt---
13
How to lower EA
  • The curve peak is the transition state (TS)
  • Enzymes bind more tightly to TS than to either
    reactants or products

14
How to lower EA
  • Mechanism form an Enzyme-Substrate (ES) complex
    at active site

15
How to lower EA
  • Mechanism form an Enzyme-Substrate (ES) complex
    at active site
  • Orient substrates properly for reaction to occur
  • Increase local concentration
  • Decrease potential for unwanted side reactions

16
How to lower EA
  • Mechanism form an Enzyme-Substrate (ES) complex
    at active site
  • Enhance substrate reactivity
  • Enhance polarity of bonds via interaction with
    amino acid functional groups
  • Possibly form covalent bonded intermediates with
    amino acid side chains

17
How to lower EA
  • Possibly form covalent bonded intermediates with
    amino acid side chains
  • Serine protease mechanism

18
How to lower EA
  • Possibly form covalent bonded intermediates with
    amino acid side chains
  • Serine protease mechanism

19
How to lower EA
  • Mechanism form an Enzyme-Substrate (ES) complex
    at active site
  • Induce bond strain
  • Alter bonding angles within substrate upon
    binding
  • Alter positions of atoms in enzyme too Induced
    fit

20
Induced fit
21
Induced fit
22
Enzyme kinetics The Michaelis-Menten Equation
S lt--gt P At low S, rate/velocity is slow,
idle time on the enzyme At very high S,
rate/velocity is maximum (Vmax), enzyme is
saturated V Vmax S/(S Km) Km S at
Vmax/2 A low Km indicates high enzyme affinity
for S (0.1mM is typical)
23
Enzyme kinetics pH and temperature dependence
24
Enzyme inhibitors
  • Irreversible
  • Form a covalent bond to an amino acid side chain
    of the enzyme active site
  • Blocks any further participation of the enzyme in
    catalysis

25
Enzyme inhibitors
  • Reversible
  • Competitive
  • bind at active site
  • Steric block to substrate binding
  • Km increased
  • Vmax not affected (increase S can overcome)

26
Enzyme inhibitors
  • Reversible
  • Noncompetitive
  • Bind at discrete site, not overlapping active
    site
  • Subtly alter enzyme structure reducing catalysis
  • Km not affected
  • Vmax decreased, (increase S cannot overcome)

Noncompetitive
Competitive
27
(No Transcript)
28
Drug discovery
  • Average cost to market 1B
  • Average time to market 13 years
  • Size of market 170B per year in US
  • S. aureus infections are a problem in hospital
    settings
  • Drug targets
  • Metabolic rxns specific to bacteria
  • Sulfa drugs (folic acid biosynthesis)
  • Cell wall synthesis
  • Penicillin, methicillin, vancomycin
  • DNA replication, transcription, translation
  • Ciprofloxacin (DNA gyrase)
  • Tetracyclins (ribosome)
  • Zyvox (ribosome)
  • Introduced in 2000, resistance observed within 1
    year of use
Write a Comment
User Comments (0)
About PowerShow.com